Tag Archives: Globally

Hot Investor Mandate 4: Germany-Based CVC with a Global Presence Invests in Innovative Medical Technologies Globally, Including Imaging & PoC and In Vitro Diagnostics

7 Jun

A corporate venture firm is headquartered in Munich, Germany, with additional offices worldwide. The fund invests in medical technology companies that are strategically relevant to the corporate’s interests. Investments in equity rounds range from $1-5 million and are made worldwide.

The firm’s primary focuses within healthcare are medical imaging (including both equipment and software) and diagnostics (particularly point of care diagnostics and molecular diagnostics). In these sectors, the firm focuses on products used in a hospital setting. The firm also invests in digital health solutions that add value to imaging and diagnostics, such as data-as-a-service products. The firm is potentially interested in medical robotics. The firm will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The firm generally does not attach strategic rights to an investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Hong Kong-based Family Office Seeking Small Molecule Therapeutics, Devices, Diagnostics, and Healthcare IT Globally

10 May

A wholly-owned venture arm of a Hong-Kong based family is focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. The firm is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

The firm seeks to invest in new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT etc. For therapeutics, the firm seeks novel small molecule and biologics and is agnostic in terms of indication. However, indications that address a large market in China are of interest. The firm looks for early stage assets in pre-clinical and phase I of clinical trials. However, the firm will not rule out assets in phase II. For devices, the firm is opportunistic in terms of the class of device.

The firm seeks an active role in its portfolio companies and generally obtain a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Technology Firm Establishes New Venture Fund for Investing in Early-Stage Digital Health Companies Globally

5 Apr

An operating group of a global public technology firm with an $18B market cap. The group began its venture portfolio in 2018 with investments in B-to-B software companies targeted at specific vertical markets such as healthcare. The fund invests $0.5M – 1M per company and is seeking companies raising seed to Series B rounds. The company is seeking 5 – 10 new investments to build their initial portfolio. The company prefers companies based in Canada, though as the parent firm is located in the US, UK, EU, and AU, the fund is open to invest globally.

The company is seeking healthcare IT, and they are particularly investing in technologies with a software component. The firm prefers commercial-stage companies, though is open to looking at clinical-stage companies as well. The company is indication agnostic.

The company will help companies fill management team positions, if necessary. The company prefers companies that are generating $100K – 3M in annual revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor 2: Venture Arm of Swiss Foundation Invests Globally in Disruptive Medtech and Digital Health Companies in Trauma and Orthopedic Surgeries

22 Mar

A venture arm of a Switzerland-based foundation invests in start-ups that fundamentally improve patient care in the area of orthopedic, spine & trauma surgery. While the firm will invest globally, the current focus is on companies located in North America, Europe and Israel. The firm prefers to participate in Series A rounds, investing between $1-2.5M with the potential to provide additional capital in later rounds. The firm’s sole investor is their parent foundation, a surgeon-led, not-for-profit organization. The foundation has a global network of more than 16,000 healthcare professionals and scientists in over 100 countries specialized in the treatment of trauma and disorders of the musculoskeletal system.

The firm looks to fund companies with disruptive technologies in medical devices, diagnostics, and healthcare IT/digital health in the trauma and orthopedic surgery space. This includes technologies for before, during or after surgery, such as imaging, surgical tools, implantable devices and clinical data management. However, the firm is not currently looking to fund any regenerative medicine or tissue engineering applications within this space. If a medical device or diagnostic, companies should have a working prototype and preclinical data, while healthcare IT/digital health companies should have a running MVP as well as the ability to show market traction.

The firm invests in teams and companies that solve fundamental problems. The firm is looking for a clear market understanding and strong USP.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: